InterCure Finalizes NIS 230M (~US$77M) War-Damages Settlement
INCR is trading near its 52-week low of $3.4 (66% below the low) on elevated volume (31× avg).
Summary
InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, providing capital to rebuild its flagship Nir Oz facility and return to full production.
Key Events · Legal and Risk Events · INCR
-
Final Settlement Reached
InterCure agreed to a final settlement of NIS 230 million (~US$77 million) with Israeli Tax Authorities and Compensation Fund for indirect damages from the October 7, 2023 attacks.
-
Claim vs. Settlement
The company's total claim exceeded NIS 300 million (~US$100 million); it had already received NIS 101 million (~US$34 million) in advance payments.
-
Nir Oz Rebuild Funded
Proceeds will accelerate rehabilitation of the Nir Oz facility, which has been inoperable since the attacks and is key to InterCure's cultivation and production.
-
German Market Expansion
Restored production is expected to support supply to the growing German medical cannabis market, a strategic growth focus.
Analysis · INCR · Life Sciences
InterCure has locked in a NIS 230 million (~US$77 million) settlement with Israeli authorities for indirect damages from the October 7, 2023 attacks. The company had claimed over NIS 300 million and already received NIS 101 million in advances, so this finalizes the remaining compensation. The cash infusion materially strengthens the balance sheet and funds the rebuild of the Nir Oz facility, which has been inoperable since the attacks and is central to InterCure's production capacity. The settlement removes a major uncertainty and provides capital to restore operations and pursue growth in the German medical cannabis market.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INCR was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.9M. The 52-week trading range was $3.40 to $8.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.